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Abstract
To standardize outcome reporting in clinical trials of patients with nonspecific low back pain, an international multidisciplinary panel
recommended physical functioning, pain intensity, and health-related quality of life (HRQoL) as core outcome domains. Given the
lack of a consensus on measurement instruments for these 3 domains in patients with low back pain, this study aimed to generate
such consensus. The measurement properties of 17 patient-reported outcome measures for physical functioning, 3 for pain
intensity, and 5 for HRQoLwere appraised in 3 systematic reviews following theCOSMINmethodology. Researchers, clinicians, and
patients (n5 207) were invited in a 2-round Delphi survey to generate consensus ($67% agreement among participants) on which
instruments to endorse. Response rates were 44% and 41%, respectively. In round 1, consensus was achieved on the Oswestry
Disability Index version 2.1a for physical functioning (78% agreement) and the Numeric Rating Scale (NRS) for pain intensity (75%
agreement). No consensuswas achieved on any HRQoL instrument, although the Short Form 12 (SF12) approached the consensus
threshold (64% agreement). In round 2, a consensus was reached on an NRS version with a 1-week recall period (96% agreement).
Various participants requested 1 free-to-use instrument per domain. Considering all issues together, recommendations on core
instruments were formulated: Oswestry Disability Index version 2.1a or 24-item Roland-Morris Disability Questionnaire for physical
functioning, NRS for pain intensity, and SF12 or 10-item PROMIS Global Health form for HRQoL. Further studies need to fill the
evidence gaps on the measurement properties of these and other instruments.
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1. Introduction
Low back pain (LBP) represents the leading cause of years lived
with disability globally, ranking first in both developed and
developing countries.46 The mean lifetime prevalence of LBP is
estimated to be 39%, with a mean point prevalence of 18%.58
The costs of LBP constitute a major burden to health care
systems and society.32,76 Most commonly, a specific pathoana-
tomical cause cannot be identified for LBP, so its most prevalent
form is nonspecific LBP (nsLBP).79 The number of randomized
controlled trials assessing the effectiveness of health interven-
tions in nsLBP has substantially increased over the past 2
decades.12
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Heterogeneity in the choice of outcomes and measurement
instruments assessed in clinical trials hampers comparisons
between studies and systematic reviews summarizing them.72,73
In several medical fields including nsLBP, this is a major
issue.53,70,77 It can be addressed by agreeing on a standardized
set of outcomes that should be measured and reported in all
clinical trials on a specific health condition: a core outcome set
(COS).7,19,113 A COS does not preclude the choice of primary or
secondary outcomes that are not in the COS, but ensures that
important outcomes are consistently assessed.7,19,113 A COS
specific to LBP was introduced 20 years ago by a group of
experienced researchers and clinicians.8,30
Deyo et al.30 and Bombardier8 proposed 5 core outcome
domains to be measured in LBP clinical research: back-specific
function, pain symptoms, generic health status, work disability,
and satisfaction with care; for each of these domains, 1 or 2
patient-reported outcome measures (PROMs) were also sug-
gested. More recently, we initiated an international Steering
Committee to build on this existing proposal, by consulting up-to-
date methodology of Core Outcome Measures in Effectiveness
Trials (COMETs) and Outcome Measures in Rheumatology
(OMERACT) initiatives6,7,92,104,111,112 to develop a COS applica-
ble to clinical trials in patients with nsLBP.22
Developing a COS is a 2-step consensus process that
involves, first, determining the core outcome domains (“core
domain set”), and second, selecting the best outcome measure-
ment instruments to measure these domains (“core outcome
measurement set”).7,19,113 For nsLBP, a consensus was
achieved on 4 core outcome domains: physical functioning, pain
intensity, health-related quality of life (HRQoL), and number of
deaths.16 The domain number of deaths was included in line with
OMERACT mandatory requirement to have at least 1 domain in
the core area “Death”7 and because it is good practice for any trial
to report on this domain; it can be covered with a simple
statement reporting how many deaths occurred in a trial.16
However, there is no consensus onmeasurement instruments for
the other 3 core outcome domains. The selection of core
outcome measurement instruments comprises the following
steps: (1) identifying potential core instruments, (2) evaluating
their measurement properties and feasibility, and (3) reaching
a consensus on those that should be recommended.6,92 The
objective of this study was to formulate recommendations on
core outcome measurement instruments for clinical trials in
patients with nsLBP.
2. Methods
An international Steering Committee, including 19 members,
worked on the development of this COS: 17 researchers and/or
clinicians (A.C., M.B., R.A.D., R.B., L.O.P.C., N.E.F., M.G., B.W.
K., F.M.K., C.-W.C.L., C.G.M., A.M.P., W.C.P., D.C.T., M.W.v.
T., C.B.T., and R.W.O.) and 2 patients’ representatives (T.P.C.
andM.L.S.). A 4-member project teamcomprising a subset of the
Steering Committee (A.C., M.B., C.B.T., and R.W.O.) oversaw
the initiative. The committee expertise included the following:
anesthesiology, epidemiology, internal medicine, orthopaedics,
physical therapy, neurosurgery, primary care, psychology, re-
habilitation, and rheumatology.
The intent was to develop a COS applicable to the
measurement of efficacy or effectiveness of health interventions
assessed in all clinical trials for patients with nsLBP, defined as
“LBP not attributable to a recognizable, known specific pathology
(eg, infection, tumour, fracture, and axial spondyloarthritis).”22
Therefore, this COS applies to all interventions, regardless of
type, setting, frequency, or mode of administration. Following
COMET and OMERACT definitions,7,113 this COS does not
prescribe primary outcomes. Rather, it recommends outcome
domains and measurement instruments that should be included
in each individual trial, alongside additional trial-specific out-
comes. The selection of instruments for physical functioning, pain
intensity, and HRQoL was guided by the OMERACT handbook,6
and the consensus-based guidance of the COnsensus-based
Standards for the selection of health Measurement INstruments
(COSMIN) initiative in cooperation with COMET.92
In the Netherlands, this type of study does not fall within the
score of the Dutch Medical Research in Human Subjects Act
(WMO), therefore it was exempt from ethical approval of
a University Ethics Committee.
2.1. Identification of potential core outcome
measurement instruments
The Steering Committee selected a preliminary set of outcome
measurement instruments for the core domains, choosing
among those frequently used in clinical trials15,44 and those
recommended by other initiatives aimed at standardizing
measurements for LBP8,24,30,31 or chronic pain.34 It was
considered that these criteria (ie, already in frequent use and
recommended by others) would facilitate implementation of this
COS. The project team performed an initial screening to
determine whether an instrument had good face validity to
measure the domain and was feasible (eg, accessibility, cost
prohibitive, and availability of translations) for inclusion in
a COS.6 A previous systematic review linking LBP-specific
PROMs content to the International Classification of Functioning
was consulted to support decisions on face validity.49 Only
PROMs were selected because they are feasible and the most
frequently used and recommended tools in the LBP
literature.8,15,24,30,31,34,44
2.2. Appraisal of measurement properties of outcome
measurement instruments
The COSMIN initiative83 previously identified 9 measurement
properties relevant for PROMs: internal consistency, test-
retest reliability, measurement error, construct validity, struc-
tural validity, criterion validity, cross-cultural validity, and
responsiveness.85 Three systematic reviews (for physical
functioning, pain intensity and HRQoL) summarized and
appraised the evidence on these measurement properties in
patients with nsLBP (Chiarotto et al., 2018. Measurement
properties of Numeric Rating Scale, Visual Analogue Scale and
Pain Severity subscale of Brief Pain Inventory in patients with
low back pain: a systematic review: Unpublished data;
Chiarotto et al., 2018. Evidence on the measurement
properties of health-related quality of life instruments is largely
missing in patients with low back pain, a systematic review:
Unpublished data; and Ref. 18). These reviews were con-
ducted according to the recently updated COSMIN method-
ology for this type of reviews (Prinsen et al., 2018. COSMIN
guideline for systematic reviews of patient-reported outcome
measures: Unpublished data); a more detailed description of
their methodology is presented elsewhere (Chiarotto et al.,
2018. Measurement properties of Numeric Rating Scale,
Visual Analogue Scale and Pain Severity subscale of Brief
Pain Inventory in patients with low back pain: a systematic
review: Unpublished data; Chiarotto et al., 2018. Evidence on
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the measurement properties of health-related quality of life
instruments is largely missing in patients with low back pain,
a systematic review: Unpublished data; and Ref. 18).
2.3. Delphi study
A consensus procedure is recommended to find an agreement
on core outcome measurement instruments.7,92 An online
modified Delphi survey was chosen as it is a widely used
method to establish a consensus on various health- and
research-related issues47,63,74,85,105; allows participation of
a broad, international, and multistakeholder panel of ‘experts’;
enables reconsideration of participants’ views based on
responses from others; and preserves anonymity among
respondents.51,98 Authors of at least 2 publications compris-
ing psychometric or clinimetric studies, randomized clinical
trials, or systematic reviews of clinical trials in patients with
nsLBP were selected to participate. This selection was
performed among 280 people invited to participate in the
Delphi study on core outcome domains for nsLBP (selected
with a systematic approach, as explained elsewhere16,22),
members of the Initiative on Methods, Measurement and Pain
Assessment in Clinical Trials (IMMPACT) executive, authors of
the 2 most recent IMMPACT publications,37,103 and 39
members of the OMERACT pain working group. To retrieve
the publications, a PubMed search was performed on October
18, 2016, by 1 reviewer (A.C.) combining authors’ names with
MESH terms and key words referring to LBP. All eligible
authors were invited for Delphi participation; all Steering
Committee members were also invited.
Two Delphi rounds were run: the first between October 19
and November 9, 2016, the second between December 13,
2016, and January 17, 2017. Before invitation, the content of
each round was pilot tested by at least 4 Steering Committee
members. Selected participants were invited to participate in
both rounds, unless they explicitly indicated that they did not
wish to participate. During each round, 2 reminders were sent
to people who had not responded. Participants were asked
about sociodemographic (eg, nationality and sex) and pro-
fessional characteristics (eg, current role and number of
clinical trials in nsLBP). Given the high LBP point preva-
lence,58 all participants were asked whether they currently
had nsLBP, and those answering positively were specifically
requested to also consider their patient perspective when
responding to the Delphi survey. These professionals were
also considered as part of the patient stakeholder group,
together with patient representatives. Proposals were pre-
sented in the Delphi survey as closed questions in which
participants could answer on a 5-point Likert scale ranging
from “Strongly disagree/Absolutely no” to “Strongly agree/
Absolutely yes” and give reasons for their answers. Because
Delphi studies rely on reaching a consensus, no sample size
calculation was required. A consensus was set a priori at 67%
of total number of participants (dis)agreeing with a proposal
(ie, “Strongly (dis)agree” and “(Dis)Agree” answers were
pooled together). This criterion is in line with previous Delphi
studies (Terwee et al., 2018. COSMIN standards and criteria
for evaluating the content validity of patient-reported outcome
measures: a Delphi study: Unpublished data; and Refs. 16,
87, 88, 90). Consistency of results was assessed by
separately calculating proportions of each stakeholder group
(ie, researchers, clinicians, and patients). The online software
SurveyMonkey (SurveyMonkey, Palo Alto, CA) was used.
2.3.1. Delphi round 1
There is a consensus that the minimum requirement to include
a PROM in a COS is that it has high quality evidence for
sufficient content validity,92 but in the systematic reviews this
criterion was not met by any instrument (Chiarotto et al., 2018.
Measurement properties of Numeric Rating Scale, Visual
Analogue Scale and Pain Severity subscale of Brief Pain
Inventory in patients with low back pain: a systematic review:
Unpublished data; Chiarotto et al., 2018. Evidence on the
measurement properties of health-related quality of life instru-
ments is largely missing in patients with low back pain,
a systematic review: Unpublished data; and Ref. 18). Despite
this, a proposal was made in the first round, before the actual
consensus procedure commenced, for recommending core
instruments based on the following reasoning: the absence of
high quality evidence does not equate to insufficient content
validity, not endorsing any instrument may hamper design and
conduct of future trials, and there is a need to update the 20-
year old recommendations.8,30 Subsequently, participants
were asked whether they agreed or disagreed with the
endorsement of each potential core instrument for inclusion
in the COS, taking into account the instrument itself, its
measurement properties, and characteristics (synthesized in
a table comparing multiple PROMs for the same domain). To
facilitate the interpretation of the summary of evidence on
measurement properties, colored smiley faces were used for
each measurement property of each instrument (eg, a green
happy smiley face indicated a high or moderate quality
evidence of sufficient results). The order of PROM presentation
was randomized across participants. Finally, 2 open questions
were asked to participants for additional potential core
instruments and for generic feedback on the Delphi and the
COS development process. One reviewer (A.C.) read all
comments and selected the most consistent and/or sub-
stantial ones for discussion together with quantitative results in
face-to-face meetings with the other members of the project
team.
2.3.2. Delphi round 2
In the second round, participants were presented with the
results of Round 1, including their own ratings, those of the
total Delphi panel and those of each stakeholder group;
a selection of illustrative comments describing participants’
reasoning was also displayed. The full feedback report with all
comments was emailed to the participants. Patient-reported
outcome measures for which there was a consensus for
endorsement in the first round were rediscussed only to
address some specific aspects (eg, feasibility and character-
istics). Patient-reported outcome measures without a consen-
sus were presented again for voting only if they had at least
50% of participants in favor of the endorsement or if any
substantial remark favored their endorsement. If no consensus
was found on any instrument for a domain, all potential core
instruments for that domain were presented again for rating.
The round concluded with an open question asking for
suggestions for the research agenda.
2.4. Recommendations on core outcome
measurement instruments
The Delphi results were discussed in a face-to-face meeting of
the project team. A first proposal on recommendations for core
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Table 1
Patient-reported outcomemeasures selected as potential core outcomemeasurement instruments to measure physical functioning, pain intensity and health-related quality of
life in clinical trials in non-specific low back pain.
PROM Name
abbreviation
Reference(s) original development Characteristics Recommended by other initiatives
aimed at fostering standardization
for LBP or chronic pain
Number of items Response options Total score
range
Recall
period
Physical functioning
Oswestry Disability Index version
1.0
ODI 1.0 Fairbank 198038 10 0-5 rating scale 0-100 Undefined Original core set for LBP clinical
research30
Oswestry Disability Index version
2.1a
ODI 2.1a Fairbank 1980,38 Meade 1986,81
Baker 19895
10 0-5 rating scale 0-100 Undefined Original core set for LBP clinical
research; ICHOM standard set for
LBP24, 30
Chiropractic version Low Back
Pain Disability Questionnaire
CLBPDQ Fairbank 1980,38 Hudson-Cook 198959 10 0-5 rating scale 0-100 Undefined
Modified version Low Back Pain
Disability Questionnaire
MLBPDQ Fairbank 1980,38 Fritz 200142 10 0-5 rating scale 0-100 Today
24-item Roland Morris Disability
Questionnaire
RMDQ-24 Roland 198394 24 0-1 yes/no 0-24 Today Original core set for LBP clinical
research30
23-item Roland Morris Disability
Questionnaire
RMDQ-23 Roland 1983,94 Patrick 199589 23 0-1 yes/no 0-23 Today Original core set for LBP clinical
research30
18-item Roland Morris Disability
Questionnaire
RMDQ-18 Roland 1983,94 Stratford 1997102 18 0-1 yes/no 0-18 Today
Pain Interference subscale of Brief
Pain Inventory
BPI-PI Daut 1983,28 Cleeland 1994,23
Cleeland 200922
7 0-10 numeric scale 0-10 Last 24 h IMMPACT for chronic pain clinical
trials34
Pain Interference items of
Multidimensional Pain Inventory
MPI-PI Kerns 198571 9 0-6 rating scale 0-6 Undefined IMMPACT for chronic pain clinical
trials34
Physical Functioning subscale of
36-item Short Form Health
Survey
SF36-PF Stewart 1992,101 Ware 1992108 10 1-3 rating scale 0-100 Now
Disability Index of Low Back Pain
Rating Scale
LBPRS-DI Manniche 199480 15 0-2 rating scale 0-30 Undefined
Quebec Back Pain Disability Scale QBPDS Kopec 199675 20 0-5 rating scale 0-80 Today
4-item Patient-Reported
Outcomes Measurement
Information System Physical
Function short form
PROMIS-PF-4 Cella 2007,14 DeWalt 2007,29 Bruce
2009,10 Fries 2009,40 Cella 2010,13
Rose 2014,95 PROMIS scientific
standards1
4 1-5 rating scale 4-20 Undefined NIH Task Force for research standards in
chronic LBP31
6-item Patient-Reported
Outcomes Measurement
Information System Physical
Function short form
PROMIS-PF-6 Cella 2007,14 DeWalt 2007,29 Bruce
2009,10 Fries 2009,40 Cella 2010,13
Rose 2014,95 PROMIS scientific
standards1
6 1-5 rating scale 6-30 Undefined
8-item Patient-Reported
Outcomes Measurement
Information System Physical
Function short form
PROMIS-PF-8 Cella 2007,14 DeWalt 2007,29 Bruce
2009,10 Fries 2009,40 Cella 2010,13
Rose 2014,95 PROMIS scientific
standards1
8 1-5 rating scale 8-40 Undefined
10-item Patient-Reported
Outcomes Measurement
PROMIS-PF-10 Cella 2007,14 DeWalt 2007,29 Bruce
2009,10 Fries 2009,40 Cella 2010,13
10 1-5 rating scale 10-50 Undefined
(continued on next page)
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Table 1 (continued)
PROM Name
abbreviation
Reference(s) original development Characteristics Recommended by other initiatives
aimed at fostering standardization
for LBP or chronic pain
Number of items Response options Total score
range
Recall
period
Information System Physical
Function short form
Rose 2014,92 PROMIS scientific
standards1
20-item Patient-Reported
Outcomes Measurement
Information System Physical
Function short form
PROMIS-PF-20 Cella 2007,14 DeWalt 2007,29 Bruce
2009,10 Fries 2009,40 Cella 2010,13
Rose 2014,95 PROMIS scientific
standards1
20 1-5 rating scale 20-99 Undefined
Pain intensity
Visual Analogue Scale VAS Huskisson 197464 1 0-100 scale 0-100 Varying
Numeric Rating Scale NRS Downie 197833 1 0-10 numeric scale 0-10 Varying Original core set for LBP clinical
research; ICHOM standard set for LBP;
NIH Task Force for research standards in
chronic LBP; IMMPACT for chronic pain
clinical trials24, 30, 31, 34
Pain Severity subscale of Brief
Pain Inventory
BPI-PS Daut 1983,29 Cleeland 1994,23
Cleeland 200922
4 0-10 numeric scale 0-10 Varying
Health-related quality of life
36-item Short Form Health Survey SF36 Ware 1992108 36 Varying 0-100* Varying Original core set for LBP clinical
research30
12-item Short Form Health Survey SF12 Ware 1996107 12 Varying 0-100† Varying Original core set for LBP clinical
research30
EuroQol Five Dimensions
questionnaire
EQ-5D EuroQol Group 1990,36 Brooks 19969 5 (items); 1 (visual analogue
scale)
1-3 rating scale (items);
0-100 visual analogue scale
0-1‡ (items); 0-
100
(visual analogue
scale)
Today Original core set for LBP clinical
research30
Nottingham Health Profile NHP Hunt 198162 45 0-1 yes/no 0-100§ At the
moment
10-item Patient-Reported
Outcomes Measurement
Information System Global
Health short form
PROMIS-GH-10 Cella 2007,14 DeWalt 2007,29 Hays
2009,54 Cella 2010,13 PROMIS scientific
standards1
9 (items); 1
(numeric scale)
1-5 rating scale (items); 0-10
(numeric scale)
4-20† Undefined
* This is the total score range for each of the 8 subscales of SF36.
† This is the total score for physical component and mental component summary scores.
‡ This is a utility score.
§ This is the total score range for the 6 domains measured by NHP part 1 (38 items); the rating for each individual item is provided for part 2 (7 items).
ICHOM, International Consortium for Health Outcomes Measurement; LBP, low back pain; PROM, patient-reported outcome measure.
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outcome measurement instruments for clinical trials in nsLBP was
formulated and sent to all members of the Steering Committee for
review. The committee feedbackwas considered in a second face-
to-face meeting of the project team, after which a refined proposal
was sent to the Steering Committee for further revision. Once
approval was obtained from all committee members, the
recommendations were considered ready for reporting.
3. Results
3.1. Potential core outcome measurement instruments
Seventeen PROMs were selected as potential core instruments
for physical functioning, 3 for pain intensity, and 5 for HRQoL
(Table 1).1,5,9,10,13,14,22,23,28,29,33,36,38,40,42,54,59,62,64,71,75,80,81,89,
94,95,101,102,107,108 There are multiple versions of both the Roland-
Morris Disability Questionnaire (RMDQ) and Oswestry Disability
Index (ODI), the most widely used physical functioning PROMs in
LBP.15,44 Several versions with sufficient face validity were
included (Table 1). The Pain Interference subscale of the Brief
Pain Inventory (BPI-PI) and the Pain Interference items of the
Multidimensional Pain Inventory (MPI-PI) were included because
they had been recommended as generic instruments to measure
physical functioning in chronic pain.34
The NIH Task Force report for research standards for chronic
LBP recommended the 4-item Patient-Reported Outcomes
Measurement Information System Physical Function short form
(PROMIS-PF-4) to measure physical functioning31; in this Delphi
the standard 4-, 6-, 8-, 10-, and 20-item PROMIS-PF short
forms2,40,95 were included as potential core instruments. The 36-
item Short Form Health Survey (SF36) is the most frequently used
PROM to measure HRQoL in LBP15 and its physical functioning
subscale (SF36-PF) was also included as a standalone in-
strument for physical functioning (Table 1). The Sickness Impact
Profile is one of themost frequently used tools tomeasureHRQoL
in LBP,15 but it was not selected because its length (ie, 136 items)
was considered excessively burdensome for inclusion in a COS.
The 10-item PROMIS Global Health short form (PROMIS-GH-10)
is not broadly used, but it was included for HRQoL as its face
validity was judged to be similar to that of the other selected
PROMs and because recently it was recommended by another
core set initiative96 (Table 1).
3.2. Measurement properties of the potential core outcome
measurement instruments
The systematic review on physical functioning PROMs revealed
low or very low quality evidence underpinning the content validity
of all the PROMs, with the exception of the 24-item RMDQ
(RMDQ-24), which displayed high quality evidence of insufficient
comprehensiveness and sufficient comprehensibility.18 High
quality evidence of insufficient unidimensionality was found for
ODI 1.0, RMDQ-24, and RMDQ-18; unidimensionality of other
PROMs was underpinned by moderate quality evidence, or no
studies were found (Appendix 2, available online as supplemental
digital content at http://links.lww.com/PAIN/A511).18 The sys-
tematic review on pain intensity PROMs highlighted that content
validity of visual analogue scale (VAS), Numeric Rating Scale
(NRS), and pain severity subscale of the Brief Pain Inventory (BPI-
PS) was underpinned by (very) low quality evidence (Appendix 2,
available online as supplemental digital content at http://links.
lww.com/PAIN/A511) (Chiarotto et al., 2018. Measurement
properties of Numeric Rating Scale, Visual Analogue Scale and
Pain Severity subscale of Brief Pain Inventory in patients with low
back pain: a systematic review. Unpublished data). High quality
evidence was found only for insufficient measurement error of the
NRS. Moderate quality evidence was found for sufficient
structural validity and internal consistency of BPI-PS, inconsistent
construct validity of BPI-PS, and inconsistent responsiveness of
NRS. There was lower quality evidence or no studies on the other
measurement properties of these 3 instruments (Appendix 2,
available online as supplemental digital content at http://links.
lww.com/PAIN/A511) (Chiarotto et al., 2018. Measurement
properties of Numeric Rating Scale, Visual Analogue Scale and
Pain Severity subscale of Brief Pain Inventory in patients with low
back pain: a systematic review. Unpublished data). In the
systematic review on HRQoL PROMs, very low quality evidence
was found on the content validity of each PROM (Appendix 2,
available online as supplemental digital content at http://links.
lww.com/PAIN/A511) (Chiarotto et al., 2018. Evidence on the
measurement properties of health-related quality of life instru-
ments is largely missing in patients with low back pain,
a systematic review. Unpublished data). High quality evidence
was found only for insufficient construct validity of EuroQol 5D
(EQ-5D) utility and VAS scores. Moderate quality evidence was
Figure 1. Flowchart of participants in the Delphi study on core outcome measurement instruments for clinical trials in nonspecific low back pain (LBP).
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found for inconsistent construct validity of component sum-
maries of the SF36 and for inconsistent responsiveness of the
EQ-5D utility score. All other measurement properties were
underpinned by lower quality evidence or not assessed
(Appendix 2, available online as supplemental digital content
at http://links.lww.com/PAIN/A511) (Chiarotto et al., 2018.
Evidence on the measurement properties of health-related
quality of life instruments is largely missing in patients with low
back pain, a systematic review. Unpublished data). A detailed
presentation of results of these reviews is available elsewhere
(Chiarotto et al., 2018. Measurement properties of Numeric
Rating Scale, Visual Analogue Scale and Pain Severity
subscale of Brief Pain Inventory in patients with low back
pain: a systematic review. Unpublished data; Unpublished
data; Chiarotto et al., 2018. Evidence on the measurement
properties of health-related quality of life instruments is largely
missing in patients with low back pain, a systematic review.
Unpublished data; and Ref. 18).
3.3. Delphi study
In total, 207 people were invited to participate in the Delphi study,
and response rates in the 2 roundswere 44%and 41%, respectively
(Fig. 1). Most participants were from the United States, the
Netherlands, United Kingdom, and Australia; the most represented
disciplines were epidemiology, physical therapy, human movement
sciences, psychology, and orthopedics (Table 2). In Round 1, 13
participants had LBP: 11 were male, mean (SD) age was 56 (8)
years, 7 were classified as nsLBP by a health care professional, 11
with pain lasting for more than 1 year, 1 with pain spreading down
the legs, and none having received a LBP operation or disability
compensation. In round 2, 14 participants reported LBP with similar
characteristics.
3.3.1. Delphi round 1
In the first round, there was a consensus (90%) to provisionally
recommend core outcome measurement instruments, despite the
absence of adequate evidence to support the PROMs’ content
validity. Several participants emphasized that core instruments
should be recommended because COS development and/or
PROM validity are moving fields in which results are always
provisional, meaning that this should not refrain from providing
recommendationson thebest available instruments. Therewas also
a consensus (90%) to reduce the list of potential core instruments for
physical functioning because for 8 of them (ODI 1.0, Chiropractic
Low Back Pain Disability Questionnaire [CLBPDQ], Modified Low
Back Pain Disability Questionnaire [MLBPDQ], RMDQ-18, LBPRS,
PROMIS-PF-4, PROMIS-PF-6, and PROMIS-PF-10), there were
also convincing arguments for not being endorsed. Main reasons
were that some of these PROMs were cross culturally adapted in
very few languages (ie, ODI 1.0, CLBPDQ, MLBPDQ, and LBPRS-
DI)18 or they could be extracted from other instruments included in
the list of potential core instruments (ie, RMDQ-18, PROMIS-PF-4,
PROMIS-PF-6, and PROMIS-PF-10).
Regarding the remaining physical functioning PROMs, 78% of
the panel agreed to endorse ODI 2.1a as a core outcome
measurement instrument, whereas 71% and 70% agreed on not
endorsing RMDQ-23 and MPI-PI, respectively (Fig. 2). No
consensus was reached on the other 6 PROMs, with Quebec
Back Pain Disability Scale (QBPDS) (62% in favor and 24%
unsure) and RMDQ-24 (50% in favor and 26% unsure) being the
Figure 2. Delphi endorsement of 9 physical functioning tools as core
outcome measurement instruments for clinical trials in nonspecific low back
pain (round 1).
Figure 3. Delphi endorsement of 3 pain intensity tools as core outcome
measurement instruments for clinical trials in nonspecific low back pain
(round 1).
Figure 4. Delphi endorsement of 4 health-related tools as core outcome
measurement instruments for clinical trials in nonspecific low back pain (round
1 and round 2).
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second and third highest in endorsement (Fig. 2). These results
were consistent across stakeholder groups.
For pain intensity, NRSwas endorsed (75%), but the panel was
split on BPI-PS (47% in favor and 24% against) and VAS (46% in
favor and 36%against) (Fig. 3). For HRQoL, the panel was unsure
for all included instruments, with the Short FormHealth Survey 12
(SF12) being the closest to endorsement (64% in favor and 21%
unsure) (Fig. 4A). Single participants suggested 11 additional
potential instruments, whereas 2 participants suggested the
PROMIS pain interference instrument. Two participants high-
lighted that the generic information supplied on the costs of using
PROMs may not be correct and that more precise costs for
each instrument should have been reported. Four participants
expressed the concern that the instruments considered may be
“dated” and 2 of these participants suggested that new instru-
ments should be developed. Two other participants criticized our
systematic reviews for pain intensity and HRQoL PROMs on the
basis that they should have included studies in all pain conditions.
Table 2
Characteristics of participants in the Delphi study.
Characteristics Round 1
(n 5 91)
Round 2
(n 5 82)
Complete answers on all questions, % 89 99
Nationality, %
United States of America 26 28
Dutch 19 16
British 13 14
Australian 9 10
Italian 5 5
Spanish 3 2
Canadian 3 4
German 2 2
Brazilian 2 2
Danish 2 1
Finnish 2 2
Norwegian 2 4
Other 12 10
Work country, %
United States of America 28 31
The Netherlands 19 15
United Kingdom 12 11
Australia 10 11
Canada 6 8
Brazil 3 4
Italy 3 4
Spain 3 2
Finland 2 2
Norway 2 4
Switzerland 2 2
Denmark 2 1
Germany 2 2
Other 6 3
Female, % 25 24
Current job activity, %
Researcher 56 56
Researcher and clinician 36 36
Clinician 6 6
Patient representative 2 2
Current presence of LBP, % 14 17
Educational background, %*
Physical therapy 35 32
Epidemiology 30 33
Human movement science 13 10
Psychology 12 9
Orthopaedics 11 12
Rheumatology 9 9
Physical medicine and rehabilitation 9 9
Internal medicine 8 7
Chiropractic 7 5
Occupational medicine 4 7
Statistics 4 1
General practice/family medicine 3 4
Osteopathy 2 1
Other 13 15
Current field of work, %*
Epidemiology 40 43
Physical therapy 29 26
Physical medicine and rehabilitation 18 16
Orthopaedics 13 12
Psychology 11 7
Rheumatology 10 10
Internal medicine 7 6
Statistics 6 4
Table 2 (continued)
Characteristics Round 1
(n 5 91)
Round 2
(n 5 82)
Human movement science 6 4
Chiropractic 3 2
Occupational medicine 3 4
Anaesthesiology 2 4
General practice/family medicine 2 1
Other 18 15
Experience with clinical trials in patients with
nsLBP, %
None 10 9
1 clinical trial 12 12
2 clinical trials 14 16
3 or more clinical trials 64 55
Missing information 0 9
Experience with systematic reviews in patients
with nsLBP, %
None 25 22
1 systematic review 17 15
2 systematic reviews 18 11
3 or more systematic reviews 40 45
Missing information 0 9
Experience in developing measurement
instruments for patients with nsLBP, %
None 46 45
1 measurement instrument 20 21
2 measurement instruments 10 6
3 or more measurement instruments 24 19
Missing information 0 9
Experience in assessing measurement
properties of instruments in nsLBP, %
None 26 23
1 study 19 18
2 studies 13 15
3 or more studies 41 35
Missing information 0 9
Experience in developing core outcome sets, %
None 48 42
1 study 32 32
2 studies 11 9
3 or more studies 8 10
Missing information 0 9
* Each participant could indicate more than one discipline.
nsLBP, nonspecific low back pain.
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3.3.2. Delphi round 2
In the second round, the exact cost for the use of each instrument
was presented together with information on characteristics and
measurement properties. Given the inconsistency of suggestions
for additional potential core instruments, none were added to this
round. For physical functioning, because a consensus on
endorsing ODI 2.1a was reached in Round 1, participants were
asked whether they could see any major argument against its
endorsement. Eleven participants responded that they were
concerned with its fees (350€/study for funded academic
research and 0€/study for nonfunded academic research),3
arguing against any fee to use instruments for measuring core
domains, expressing concerns that it could represent a barrier for
funded academic research in low- and middle-income countries,
and that fees might be increased once an instrument is
recommended as core (Appendix 3, available online as supple-
mental digital content at http://links.lww.com/PAIN/A511).
QBPDS and RMDQ-24 were presented again but no consensus
was reached on their endorsement (ie, 54% in favor and 27%
against for QBPDS, 52% in favor and 33% against for RMDQ-24).
For pain intensity, because a consensus on endorsing NRSwas
achieved in round 1, participants were asked whether they agreed
on endorsing an NRS referring to “average LBP intensity over the
last week” in the introductory statement (Appendix 1, available
online as supplemental digital content at http://links.lww.com/
PAIN/A511), similar to other recommendations for LBP.24,31 A
strong consensus (96%) was achieved on endorsing this NRS
version. For HRQoL, results were similar to round 1, with the SF12
being the highest on endorsement (51% in favor and 22% unsure)
(Fig. 4B). The main reasons against endorsing these instruments
were overlap of their content with physical functioning and pain
intensity instruments; scarce validity for measuring HRQoL for EQ-
5D; unfamiliarity and lack of testing in nsLBP for PROMIS-GH-10;
high costs for SF36 and SF12; and excessive length of SF36.
Various suggestions for the research agendaweremade by the
participants, with the most consistent being to investigate the
measurement properties not fully assessed so far (9 participants),
perform head-to-head comparison studies on measurement
studies of recommended and not recommended PROMs (6),
take PROMIS instruments more into account (4), develop a better
outcome measurement instrument for LBP (3), develop a new
instrument for HRQoL (2), develop an instrument for LBP that
takes into account other constructs (eg, social participation) (2),
use instruments that can be administered with computerized
adaptive testing (CAT) (2), consider the recently developed
Musculoskeletal Health Questionnaire56 in future clinimetric
studies (2), and assess the minimal important difference of the
various instruments to explore whether it differs depending on
patient characteristics and interventions (2).
3.4. Recommendations on core outcome
measurement instruments
Considering the Delphi process results, the Steering Committee
discussed and formulated a set of recommendations on
measurement instruments to be used in nsLBP clinical trials
(Table 3). This includes ODI 2.1a and NRS to measure physical
functioning and pain intensity, respectively. Given the concerns of
Delphi participants and some committeemembers on theODI 2.1a
fees, the instrument’s distributor was contacted to ask iwhether it
was possible to eliminate or reduce the ODI 2.1a fee for funded
academic research. Because this was not possible, the Steering
Committee decided to also recommend the RMDQ-24 for physical
functioning because it achieved the highest level of consensus
among the free-to-use instruments (Fig. 2), but also because its
measurement properties resemble those of ODI 2.1a in head-to-
head comparisons studies.17 Despite a similar level of endorse-
ment and measurement properties, the QBPDS was not recom-
mended because of the same fee issue as theODI 2.1a and also to
limit the number of instruments for a single core domain.
The NRS with a 1-week recall period (Appendix 1, available
online as supplemental digital content at http://links.lww.com/
PAIN/A511) should be used to measure pain intensity in nsLBP
trials. Because it is a free tool that obtained ample consensus in
the Delphi, the Steering Committee does not recommend
another instrument for pain intensity. However, researchers
should note the limitations in its use for acute nsLBP trials when
participants may have had pain for less than 1 week at
baseline.41,110 In these trials, the addition of an NRS with
a 24-hour recall period is suggested.
Despite the lack of a consensus formeasuringHRQoL, to reduce
measurement variability for this domain, we recommend the use of
the SF12 as it was closest to a consensus (Fig. 4), but because it is
not free of charge, the PROMIS-GH-10 is also recommended
(Table 3). Both PROMs provide a physical and a mental summary
score (Table 1), which allows pooling of their results in meta-
analysis. The SF36 is not recommended because of its length. The
EQ-5D is not recommended because of its cost; it results in a utility
index,which is not possible to poolwith data fromother instruments
and its content is strongly redundant given the domains physical
functioning and pain intensity. However, the Steering Committee
suggests inclusion of the EQ-5D (preferably EQ-5D-5L version55,65)
in nsLBP clinical trials if there is an economic evaluation.
No specific recommendations regarding time frames of out-
come assessment and reporting of adverse events aremade in line
with theNIHTask ForceReport for chronic LBP suggestion.31 Time
frames should match the specific goals and feasibility of each
clinical trial. Potential adverse events should preferably be specified
before the start of a clinical trial and measured prospectively. The
Steering Committee suggests the use of previous consensus-
based recommendations for reporting of outcome results43 and for
interpreting change scores on core instruments.35,86
4. Discussion
This study formulates recommendations on core outcome
measurement instruments for use in nsLBP trials (Table 3). They
comprise theODI 2.1a or RMDQ-24 for physical functioning, NRS
with a 1-week recall period for pain intensity, and SF12 or
PROMIS-GH-10 for HRQoL. In addition, a simple statement
reporting whether any death occurred in a clinical trial is
recommended.16 These recommendations update the previous
LBP outcome recommendations of Deyo et al.30 and Bombar-
dier.8 This COS applies to both acute and chronic nsLBP, and in
the latter group, it complements the baseline research standards
recommended by the NIH Task Force Report.31
4.1. Recommendations for future research
A recommended process that involved identification and review
of measurement properties for candidate instruments and
a consensus process for final selection was followed.6,92 This
core outcome measurement set is preliminary because high
quality evidence is lacking for several measurement properties of
various PROMs (Chiarotto et al., 2018. Measurement properties
of Numeric Rating Scale, Visual Analogue Scale and Pain Severity
subscale of Brief Pain Inventory in patients with low back pain:
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a systematic review. Unpublished data; Chiarotto et al., 2018.
Evidence on the measurement properties of health-related
quality of life instruments is largely missing in patients with low
back pain, a systematic review. Unpublished data; and Ref.
18). In particular, there is an urgent need to better assess and
compare content validity, structural validity, reliability, and
responsiveness of the recommended instruments with other
instruments (Chiarotto et al., 2018. Measurement properties of
Numeric Rating Scale, Visual Analogue Scale and Pain
Severity subscale of Brief Pain Inventory in patients with low
back pain: a systematic review. Unpublished data; Chiarotto et
al., 2018. Evidence on the measurement properties of health-
related quality of life instruments is largely missing in patients
with low back pain, a systematic review. Unpublished data;
and Ref. 18). Developing a COS is an iterative process that
should be updated if new evidence emerges on outcome
domains or measurement instruments. Therefore, these
recommendations are likely to evolve in the future.
Cross-cultural validity has not been investigated for the
recommended instruments or other candidate PROMs (Chiarotto
et al., 2018. Measurement properties of Numeric Rating Scale,
Visual Analogue Scale and Pain Severity subscale of Brief Pain
Inventory in patients with low back pain: a systematic review:
Unpublished data; Chiarotto et al., 2018. Evidence on the
measurement properties of health-related quality of life instru-
ments is largely missing in patients with low back pain,
a systematic review: Unpublished data; and Ref. 18). This
measurement property assesses whether the performance of
the items on a translated or culturally adapted PROM is an
adequate reflection of the performance of the items of the original
version.85 It can be evaluated using data from several countries to
assess differential item functioning,26,100 and it would give a clear
indication on the appropriateness of pooling data on the same
PROM from different countries.
4.1.1. Physical functioning
Roland-Morris Disability Questionnaire and ODI were included
in earlier recommendations for physical functioning in LBP,8,30
but this report gives more precise recommendations on which
versions to use (Table 3). The International Consortium for
Health Outcomes Measurement standard set for LBP also
recommended ODI 2.1a to measure physical functioning
because it “is the most heavily studied, providing superior
interpretability” and “the most feasible to implement as it has
been validated in 14 languages (…) and is relatively short.”24
One systematic review showed that from a measurement point
of view, there are no strong reasons to prefer ODI 2.1a over
RMDQ-24 in patients with nsLBP.17 Moreover, the RMDQ-24
is available in some languages in which the ODI 2.1a is not.18
There is high quality evidence suggesting that RMDQ-24 has
limitations in key aspects of validity such as comprehensive-
ness and unidimensionality,18 but its (content and structural)
validity has never been directly compared with that of ODI 2.1a
in the same group of patients with LBP.17
Direct head-to-head comparisons of instruments should be
extended to include other recently suggested instruments to
measure physical functioning in LBP (eg, QBPDS or PROMIS-
PF short forms).21,31,99 Comparing the content validity has the
highest priority because this is the first measurement property
that should be evaluated when selecting PROMs for a COS.92
The measurement properties of PROMIS-PF instruments have
been assessed in the generic population or in a heterogeneous
spine or pain population,10,25,27,40,60,61,88,95,97 but there is
little evidence in patients with nsLBP. A recent study compared
unidimensionality and item response theory performance of
PROMIS-PF short forms with the RMDQ-24 in patients with
chronic nsLBP, finding promising results in favor of PROMIS-
PF short forms (Chiarotto et al., 2018. The 4-, 6-, 8- and 10-
item PROMIS Physical Function short forms have better
psychometric performance than the 24-item Roland Morris
Disability Questionnaire: Unpublished data). It should be noted
that there is a lively debate on the question whether generic
instruments should be tested in each specific disease
population or not.78,113
The PROMIS-PF item bank was also developed to admin-
ister computerized adaptive testing (CAT) forms (ie, PROMIS-
PF-CAT40), however CAT instruments have not been consid-
ered for LBP outcome standardization because they are not
yet feasible for use in every trial internationally. Nonetheless,
researchers should also test CAT forms because CAT
simulations were demonstrated to provide increased mea-
surement efficiency and precision.27,40 Some participants of
this Delphi study suggested that new outcome measurement
instruments should be developed for LBP, but we are hesitant
Table 3
Core outcome measurement instruments for clinical trials in nonspecific low back pain.
Core outcome domain Instrument Free of charge? Availability
Physical functioning Oswestry Disability Index version 2.1a (ODI
2.1a)
Yes for not funded academic users; no for
funded academic and commercial users
https://eprovide.mapi-trust.org/instruments/
oswestry-disability-index
24-item Roland Morris Disability Questionnaire
(RMDQ-24)
Yes http://www.rmdq.org/download.htm
Pain intensity Numeric Rating Scale (NRS)* Yes Appendix 1
Health-related quality of
life
Short Form Health Survey 12 (SF12) No, costs are established on a per study basis https://campaign.optum.com/optum-
outcomes/what-we-do/health-surveys/sf-
12v2-health-survey.html
10-item PROMIS Global Health (PROMIS-GH-
10)
Yes http://www.healthmeasures.net/administrator/
components/com_instruments/uploads/Global
%20Health%20Scale%20v1.2%
2008.22.2016.pdf
No. of deaths A simple statement on the number of deaths
occurring in the trial
Yes
* A consensus was achieved on a Numeric Rating Scale version that refers to average low back pain intensity over the past week in the introductory statement, as presented in Appendix 1, available online as supplemental digital
content at http://links.lww.com/PAIN/A511.
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to suggest this as a high research priority because many
PROMs to measure physical functioning are already avail-
able48 and efforts may be better spent on generating evidence
on the key measurement properties of these instruments.
4.1.2. Pain intensity
An NRS with a 1-week recall period has been repeatedly
suggested as a key instrument for pain intensity in LBP,21,24,31
and these previous suggestions strengthen our recommen-
dation. Although the evidence base for this tool was of low
quality in nsLBP (Chiarotto et al., 2018. Measurement
properties of Numeric Rating Scale, Visual Analogue Scale
and Pain Severity subscale of Brief Pain Inventory in patients
with low back pain: a systematic review. Unpublished data).
There is a larger body of evidence in other pain conditions
suggesting that its measurement properties are satisfac-
tory.52,57,67 Nevertheless, pain-rating scales definitely present
some shortcomings, such as capturing multiple dimensions of
the pain experience, and not only its intensity.39,93,109 For this
reason, we decided to add the key word “intensity” in the
recommended NRS, and more studies exploring the patients’
perspective on these tools are needed. A few studies
have directly compared the measurement performance of
single-itemNRSwith that of multiitem instruments (eg, BPI-PS)
and suggested that single-item instruments may be
acceptable.66,68,69
4.1.3. Health-related quality of life
Reaching a consensus on a single instrument for HRQoL
proved to be challenging. This highlights various issues with
the domain and its instruments. Compared with physical
functioning and pain intensity, HRQoL displayed a lower level
of consensus for inclusion in this COS;16 it has a broad
definition, is multidimensional in nature, and has been less
frequently assessed in LBP clinical trials.46 Moreover, only the
construct validity of commonly used PROMs has been
adequately assessed in patients with nsLBP (Chiarotto et al.,
2018. Evidence on the measurement properties of health-
related quality of life instruments is largely missing in patients
with low back pain, a systematic review. Unpublished data).
Low back pain is considered as a multidimensional biopsy-
chosocial pain disorder,90,106 and some authors
have advocated the use of multidimensional instruments to
fully capture the complexity of treatment response.45,50
Health-related quality of life is a domain that meets the LBP
multidimensional nature, and this may be a sufficient reason to
make an effort to better define this domain for patients with
nsLBP, taking into account all the aspects that impact and
burden their life.11,45 New back-specific or musculoskeletal-
specific PROMs, such as instruments based on the Interna-
tional Classification of Functioning LBP core set4 or the
Musculoskeletal Health Questionnaire,56 should be consid-
ered in future clinimetric studies for a direct comparison with
the generic instruments recommended here.
4.2. Strengths and weaknesses
Overall, the main strengths of the current study are the
thorough assessment of the measurement properties of
candidate instruments (Chiarotto et al., 2018. Measurement
properties of Numeric Rating Scale, Visual Analogue Scale and
Pain Severity subscale of Brief Pain Inventory in patients with
low back pain: a systematic review: Unpublished data;
Chiarotto et al., 2018. Evidence on the measurement
properties of health-related quality of life instruments is largely
missing in patients with low back pain, a systematic review:
Unpublished data; and Ref. 18) and transparency in each
stage of the study (eg, providing full feedback reports to Delphi
participants). The systematic reviews were conducted accord-
ing to the most recent COSMIN methodology (Prinsen et al.,
2018. COSMIN guideline for systematic reviews of patient-
reported outcome measures: Unpublished data; Terwee et al.,
2018. COSMIN standards and criteria for evaluating the
content validity of patient-reported outcome measures:
a Delphi study: Unpublished data; and Refs. 82,85). and
included a thorough assessment of the content validity of the
instruments as well as information about their development
phase. The Delphi participants were presented with summary
information on the potential core instruments, including
measurement properties and availability and, therefore, had
the opportunity to make informed decisions, taking into
account the instruments’ content also. This is the first study
to perform a consensus procedure on core outcome mea-
surement instruments for nsLBP and the first one to use
a Delphi survey to seek a consensus on instruments for any
health condition. Another strength of this project is that the
selected outcome domains and measurement instruments
represent those for which there is a consensus across relevant
stakeholders in the nsLBP field. Therefore, it is reasonable to
suggest that these recommendations may also apply to
observational studies or routine clinical practice.
A limitation of our study regards the Delphi panel selection. It
included a selected sample of researchers, clinicians, and
patient representatives that may not generalize to the whole
LBP community. We attempted to be comprehensive in
inviting participants and we have described the sample
appropriately (Table 2), but our sample may not be fully
representative. Another potential limitation is that “ordinary”
patients were not involved in the consensus procedure.
Nevertheless, it should be underlined that it remains unclear
how patients can contribute to the selection of core instru-
ments taking aspects like measurement properties into
account, and methodological research in this field is lacking.
In addition, all existing studies in which patients with nsLBP
were asked about their perspective on the potential core
instruments were included in the 3 systematic reviews and this
became part of the content validity evidence synthesis
presented in the Delphi survey. Another limitation may be that
potential core instruments were selected among those most
frequently used and recommended, potentially overlooking
some more recent, less frequently used, and/or investigated
tools; however, it should be also noted that PROMIS instru-
ments were included in our consensus procedure to partly
address this issue. Delphi open-ended questions were
reviewed and categorized by only 1 reviewer with no double
checking by a second one; this may also represent a potential
limitation of this study.
5. Conclusions
In summary, this study has formulated a preliminary core
outcome measurement set specifying instruments to be
included in every clinical trial in patients with nsLBP
(Table 3). These recommendations will be updated as further
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evidence on the measurement properties of recommended
and alternative instruments becomes available.
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